眼科用医薬品の市場規模、シェア、動向分析レポート：薬剤クラス別、疾患別、剤形タイプ別、投与経路別、製品タイプ別、製品別、地域別、セグメント別予測、2024年～2030年

眼科用医薬品市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の眼科用医薬品市場規模は2030年までに655億5,000万米ドルに達し、2023年から2030年までのCAGRは7.80%に達する見込みです。

眼科疾患に対する意識の高まりと眼科用医薬品に対する需要の急増が市場成長を促進する要因です。さらに、加齢黄斑変性、白内障、ドライアイ、糖尿病網膜症、緑内障などの眼疾患の有病率の増加が、眼科用医薬品の需要を押し上げると予測されています。

BrightFocus Foundationによると、2021年には300万人以上の米国人が緑内障を患っていると推定され、そのうち270万人以上の患者が最も一般的なタイプの緑内障、すなわち開放隅角緑内障に罹患しています。さらに、米国では330万人が失明や弱視の影響を受けています。緑内障や失明の主な危険因子としては、高年齢、家族歴、角膜の薄さ、眼圧の高さなどが挙げられます。このため、眼科用医薬品に対する幅広い人口基盤が形成され、有利な成長が確実なものとなっています。

さらに、眼科用医薬品やドラッグデリバリー企業は、新薬開発のための技術進歩のための研究開発を促進するための資金援助を受けており、これが市場の成長を促進する可能性が高いです。例えば、2020年6月、Re-Vana Therapeutics社は、Qubis社、ExSight Ventures, LLC社、Clarendon Fund Managers社、Visionary Ventures社、Techstart Ventures LLP社からプレシリーズAで325万米ドルの資金提供を受けました。この資金調達により、リ・ヴァナ・セラピューティクスのEyeLiefとOcuLiefの生分解性技術の開発が促進され、低分子だけでなく生物製剤の送達にも使用できるようになると期待されています。

さらに、老人人口の増加が眼科用医薬品市場成長の主な促進要因となっています。Safe Eyes Americaによると、眼科疾患の最も一般的な危険因子は、高年齢、家族歴、糖尿病、高血圧です。例えば、AMERICA's HEALTH RANKINGS senior report 2021によると、米国には65歳以上の成人が5,400万人以上住んでおり、その人口は総人口の16.5%を占めると推定されています。黄斑変性症調査によると、AMDは60歳以上の米国人の失明原因の第1位です。

眼科用製品に対する継続的な薬事承認が市場の成長を支えていると思われます。例えば、参天製薬株式会社は2022年6月、ドライアイ治療薬ディクアスLX点眼液の日本における製造販売承認を取得したと発表しました。この点眼液は、投与回数を減らし、患者のコンプライアンスを向上させた改良型製剤です。

眼科用医薬品市場レポートハイライト

• 抗VEGF薬セグメントは、需要の高まりと副作用の少なさから2022年に最大のシェアを占めました。
• 網膜障害は、加齢黄斑変性と糖尿病性網膜症の有病率の上昇により、2022年に最大の市場シェアを占めました。
• 局所投与経路が2022年に市場を独占したのは、薬剤を標的部位に送達する局所投与経路の利点や使いやすさなどの要因によるものです。
• 点眼薬の需要の高まり、患者のコンプライアンスの高さ、OTC製品の入手のしやすさなどから、2022年には点眼薬部門が最大のシェアを占めると予想されます。
• アジア太平洋地域は、ヘルスケアインフラの進歩、眼科製品の需要増加、患者数の多さから、予測期間中に最も速い成長を示すと予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 眼科用医薬品市場：変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 眼科用医薬品市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • 価格分析
  • パイプライン分析
  • 特許失効の分析

第4章 眼科用医薬品市場：薬剤クラスの推定・動向分析

• 薬剤クラスの市場シェア、2023年と2030年
• セグメントダッシュボード
• 薬剤クラス別の世界の眼科用医薬品市場の見通し
• 市場規模、予測および動向分析、2018年から2030年まで

第5章 眼科用医薬品市場：疾患の推定・動向分析

• 疾患の市場シェア、2023年と2030年
• セグメントダッシュボード
• 疾患別の世界の眼科用医薬品市場の見通し
• 市場規模、予測および動向分析、2018年から2030年まで

第6章 眼科用医薬品市場：投与経路の推定・動向分析

• 投与経路の市場シェア、2023年と2030年
• セグメントダッシュボード
• 投与経路別の世界の眼科用医薬品市場の見通し
• 市場規模、予測および動向分析、2018年から2030年まで

第7章 眼科用医薬品市場：剤形タイプの推定・動向分析

• 剤形タイプの市場シェア、2023年と2030年
• セグメントダッシュボード
• 剤形タイプ別の世界の眼科用医薬品市場の見通し
• 市場規模、予測および動向分析、2018年から2030年まで

第8章 眼科用医薬品市場：製品タイプの推定・動向分析

• 製品タイプの市場シェア、2023年と2030年
• セグメントダッシュボード
• 製品タイプ別の世界の眼科用医薬品市場の見通し
• 市場規模、予測および動向分析、2018年から2030年まで

第9章 眼科用医薬品市場：製品の推定・動向分析

• 製品の市場シェア、2023年と2030年
• セグメントダッシュボード
• 製品別の世界の眼科用医薬品市場の見通し
• 市場規模、予測および動向分析、2018年から2030年まで

第10章 眼科用医薬品市場：地域の推定・動向分析

• 地域の市場シェア分析、2023年と2030年
• 地域の市場ダッシュボード
• 世界の地域の市場スナップショット
• 市場規模と予測動向分析、2018年から2030年
• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 会社/競合の分類
• ベンダー情勢
  • Pfizer Inc.
  • Alcon
  • Novartis AG
  • Bausch Health Companies Inc.
  • Merck &Co., Inc.
  • Regeneron Pharmaceuticals Inc.
  • Allergan（AbbVie Inc）
  • Bayer AG
  • Genentech, Inc.（F. Hoffmann-La Roche Ltd）
  • Nicox
  • Coherus BioSciences

List of Tables

• Table 1 List of abbreviation
• Table 2 North America ophthalmic drugs market, by region 2018 - 2030 (USD Billion)
• Table 3 North America ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 4 North America ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 5 North America ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 6 North America ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 7 North America ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 8 North America ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 9 U.S. ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 10 U.S. ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 11 U.S. ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 12 U.S. ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 13 U.S. ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 14 U.S. ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 15 Canada ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 16 Canada ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 17 Canada ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 18 Canada ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 19 Canada ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 20 Canada ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 21 Europe ophthalmic drugs market, by region 2018 - 2030 (USD Billion)
• Table 22 Europe ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 23 Europe ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 24 Europe ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 25 Europe ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 26 Europe ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 27 Europe ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 28 Germany ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 29 Germany ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 30 Germany ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 31 Germany ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 32 Germany ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 33 Germany ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 34 UK ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 35 UK ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 36 UK ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 37 UK ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 38 UK ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 39 UK ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 40 France ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 41 France ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 42 France ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 43 France ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 44 France ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 45 France ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 46 Italy ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 47 Italy ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 48 Italy ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 49 Italy ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 50 Italy ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 51 Italy ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 52 Spain ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 53 Spain ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 54 Spain ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 55 Spain ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 56 Spain ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 57 Spain ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 58 Denmark ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 59 Denmark ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 60 Denmark ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 61 Denmark ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 62 Denmark ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 63 Denmark ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 64 Sweden ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 65 Sweden ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 66 Sweden ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 67 Sweden ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 68 Sweden ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 69 Sweden ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 70 Norway ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 71 Norway ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 72 Norway ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 73 Norway ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 74 Norway ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 75 Norway ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 76 Asia Pacific ophthalmic drugs market, by region 2018 - 2030 (USD Billion)
• Table 77 Asia Pacific ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 78 Asia Pacific ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 79 Aisa Pacific ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 80 Aisa Pacific ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 81 Aisa Pacific ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 82 Aisa Pacific ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 83 China ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 84 China ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 85 China ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 86 China ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 87 China ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 88 China ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 89 Japan ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 90 Japan ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 91 Japan ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 92 Japan ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 93 Japan ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 94 Japan ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 95 India ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 96 India ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 97 India ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 98 India ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 99 India ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 100 India ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 101 South Korea ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 102 South Korea ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 103 South Korea ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 104 South Korea ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 105 South Korea ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 106 South Korea ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 107 Australia ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 108 Australia ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 109 Australia ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 110 Australia ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 111 Australia ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 112 Australia ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 113 Thailand ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 114 Thailand ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 115 Thailand ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 116 Thailand ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 117 Thailand ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 118 Thailand ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 119 Latin America ophthalmic drugs market, by region 2018 - 2030 (USD Billion)
• Table 120 Latin America ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 121 Latin America ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 122 Latin America ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 123 Latin America ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 124 Latin America ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 125 Latin America ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 126 Brazil ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 127 Brazil ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 128 Brazil ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 129 Brazil ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 130 Brazil ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 131 Brazil ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 132 Mexico ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 133 Mexico ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 134 Mexico ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 135 Mexico ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 136 Mexico ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 137 Mexico ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 138 Argentina ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 139 Argentina ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 140 Argentina ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 141 Argentina ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 142 Argentina ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 143 Argentina ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 144 MEA ophthalmic drugs market, by region 2018 - 2030 (USD Billion)
• Table 145 MEA ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 146 MEA ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 147 MEA ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 148 MEA ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 149 MEA ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 150 MEA ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 151 South Africa ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 152 South Africa ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 153 South Africa ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 154 South Africa ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 155 South Africa ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 156 South Africa ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 157 Saudi Arabia ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 158 Saudi Arabia ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 159 Saudi Arabia ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 160 Saudi Arabia ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 161 Saudi Arabia ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 162 Saudi Arabia ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 163 UAE ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 164 UAE ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 165 UAE ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 166 UAE ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 167 UAE ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 168 UAE ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
• Table 169 Kuwait ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
• Table 170 Kuwait ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
• Table 171 Kuwait ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
• Table 172 Kuwait ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
• Table 173 Kuwait ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
• Table 174 Kuwait ophthalmic drugs market, by product 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Ophthalmic drugs market: market outlook
• Fig. 14 Tumor ablation competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Penetration and growth prospect mapping
• Fig. 18 Industry value chain analysis
• Fig. 19 Ophthalmic drugs market driver impact
• Fig. 20 Ophthalmic drugs market restraint impact
• Fig. 21 Ophthalmic drugs market strategic initiatives analysis
• Fig. 22 Ophthalmic drugs market: Drug class movement analysis
• Fig. 23 Ophthalmic drugs market: Drug class outlook and key takeaways
• Fig. 24 Anti-allergy market estimates and forecast, 2018 - 2030
• Fig. 25 Anti-VEGF agents estimates and forecast, 2018 - 2030
• Fig. 26 Anti-inflammatory market estimates and forecast, 2018 - 2030
• Fig. 27 Anti-glaucoma estimates and forecast, 2018 - 2030
• Fig. 28 Gene and cell therapy market estimates and forecast, 2018 - 2030
• Fig. 29 Others estimates and forecast, 2018 - 2030
• Fig. 30 Ophthalmic drugs market: Disease movement analysis
• Fig. 31 Ophthalmic drugs market: Disease outlook and key takeaways
• Fig. 32 Dry eye market estimates and forecast, 2018 - 2030
• Fig. 33 Allergies estimates and forecast, 2018 - 2030
• Fig. 34 Glaucoma market estimates and forecast, 2018 - 2030
• Fig. 35 Infection estimates and forecast, 2018 - 2030
• Fig. 36 Retinal disorders market estimates and forecast, 2018 - 2030
• Fig. 37 Uveitis estimates and forecast, 2018 - 2030
• Fig. 38 Others estimates and forecast, 2018 - 2030
• Fig. 39 Ophthalmic drugs market: Route of administration movement analysis
• Fig. 40 Ophthalmic drugs market: Route of administration outlook and key takeaways
• Fig. 41 Topical market estimates and forecast, 2018 - 2030
• Fig. 42 Local ocular estimates and forecast, 2018 - 2030
• Fig. 43 Systemic market estimates and forecast, 2018 - 2030
• Fig. 44 Ophthalmic drugs market: Dosage type movement analysis
• Fig. 45 Ophthalmic drugs market: Dosage type outlook and key takeaways
• Fig. 46 Gels market estimates and forecast, 2018 - 2030
• Fig. 47 Eye solutions and suspensions estimates and forecast, 2018 - 2030
• Fig. 48 Capsules and tablets market estimates and forecast, 2018 - 2030
• Fig. 49 Eye drops estimates and forecast, 2018 - 2030
• Fig. 50 Ointments market estimates and forecast, 2018 - 2030
• Fig. 51 Ophthalmic drugs market: Product type movement analysis
• Fig. 52 Ophthalmic drugs market: Product type outlook and key takeaways
• Fig. 53 OTC market estimates and forecast, 2018 - 2030
• Fig. 54 Prescription drugs estimates and forecast, 2018 - 2030
• Fig. 55 Ophthalmic drugs market: Product movement Analysis
• Fig. 56 Ophthalmic drugs market: Product outlook and key takeaways
• Fig. 57 Branded drugs market estimates and forecasts, 2018 - 2030
• Fig. 58 Generic drugs market estimates and forecasts,2018 - 2030
• Fig. 59 Global ophthalmic drugs market: Regional movement analysis
• Fig. 60 Global ophthalmic drugs market: Regional outlook and key takeaways
• Fig. 61 Global ophthalmic drugs market share and leading players
• Fig. 62 North America market share and leading players
• Fig. 63 Europe market share and leading players
• Fig. 64 Asia Pacific market share and leading players
• Fig. 65 Latin America market share and leading players
• Fig. 66 Middle East & Africa market share and leading players
• Fig. 67 North America: SWOT
• Fig. 68 Europe SWOT
• Fig. 69 Asia Pacific SWOT
• Fig. 70 Latin America SWOT
• Fig. 71 MEA SWOT
• Fig. 72 North America, by country
• Fig. 73 North America
• Fig. 74 North America market estimates and forecasts, 2018 - 2030
• Fig. 75 U.S. key country dynamics
• Fig. 76 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 77 Canada key country dynamics
• Fig. 78 Canada market estimates and forecasts, 2018 - 2030
• Fig. 79 Europe
• Fig. 80 Europe market estimates and forecasts, 2018 - 2030
• Fig. 81 UK key country dynamics
• Fig. 82 UK market estimates and forecasts, 2018 - 2030
• Fig. 83 Germany key country dynamics
• Fig. 84 Germany market estimates and forecasts, 2018 - 2030
• Fig. 85 France key country dynamics
• Fig. 86 France market estimates and forecasts, 2018 - 2030
• Fig. 87 Italy key country dynamics
• Fig. 88 Italy market estimates and forecasts, 2018 - 2030
• Fig. 89 Spain key country dynamics
• Fig. 90 Spain market estimates and forecasts, 2018 - 2030
• Fig. 91 Denmark key country dynamics
• Fig. 92 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 93 Sweden key country dynamics
• Fig. 94 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 95 Norway key country dynamics
• Fig. 96 Norway market estimates and forecasts, 2018 - 2030
• Fig. 97 Asia Pacific
• Fig. 98 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 99 China key country dynamics
• Fig. 100 China market estimates and forecasts, 2018 - 2030
• Fig. 101 Japan key country dynamics
• Fig. 102 Japan market estimates and forecasts, 2018 - 2030
• Fig. 103 India key country dynamics
• Fig. 104 India market estimates and forecasts, 2018 - 2030
• Fig. 105 Thailand key country dynamics
• Fig. 106 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 107 South Korea key country dynamics
• Fig. 108 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 109 Australia key country dynamics
• Fig. 110 Australia market estimates and forecasts, 2018 - 2030
• Fig. 111 Latin America
• Fig. 112 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 113 Brazil key country dynamics
• Fig. 114 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 115 Mexico key country dynamics
• Fig. 116 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 117 Argentina key country dynamics
• Fig. 118 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 119 Middle East and Africa
• Fig. 120 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 121 South Africa key country dynamics
• Fig. 122 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 123 Saudi Arabia key country dynamics
• Fig. 124 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 125 UAE key country dynamics
• Fig. 126 UAE market estimates and forecasts, 2018 - 2030
• Fig. 127 Kuwait key country dynamics
• Fig. 128 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 129 Market share of key market players- Ophthalmic drugs market

Ophthalmic Drugs Market Growth & Trends:

The global ophthalmic drugs market size is expected to reach USD 65.55 billion by 2030, garnering a CAGR of 7.80% from 2023 to 2030, according to a new report by Grand View Research, Inc. The rising awareness about ophthalmic disorders and the surge in demand for ophthalmic drugs are the factors propelling the market growth. Moreover, an increase in the prevalence of eye diseases such as age-related macular degeneration, cataract, dry eye, diabetic retinopathy, glaucoma, and others are anticipated to boost the demand for ophthalmic drugs.

According to BrightFocus Foundation in 2021, it is estimated that over 3 million Americans are living with glaucoma, and, among them over 2.7 million patients were affected by the most common type of glaucoma i.e. open-angle glaucoma. Moreover, 3.3 million people are affected by blindness and low vision in the U.S. Some of the major risk factors for glaucoma and blindness are, higher age, family history, thin cornea, and high eye pressure. This creates a wide population base for ophthalmic drugs, thereby, ensuring lucrative growth.

Furthermore, ocular therapeutic and drug delivery companies are receiving funding to expedite R&D for advancements in technologies to develop novel drugs, which is likely to fuel market growth. For instance, in June 2020, Re-Vana Therapeutics received USD 3.25 million in pre-series A funding from Qubis, ExSight Ventures, LLC, Clarendon Fund Managers, Visionary Ventures, and Techstart Ventures LLP. The funding is expected to boost the development of Re-Vana Therapeutics' EyeLief & OcuLief biodegradable technologies that can be used for a small molecule as well as biologics delivery.

Moreover, the rising geriatric population is the key driver for the ophthalmic drugs market growth. According to Safe Eyes America, the most common risk factors for ophthalmic diseases are high age, family history, diabetes, and high blood pressure. For instance, as per AMERICA's HEALTH RANKINGS senior report 2021 it was estimated that more than 54 million adults of age more than 65 live in the U.S., and that population accounted for 16.5% of the total population. According to Macular Degeneration Research AMD is the leading reason for blindness in U.S. people over the age of 60.

Ongoing regulatory approvals for ophthalmic products are likely to support market growth. For instance, in June 2022 Santen Pharmaceutical Co., Ltd announced that it has got marketing and manufacturing approval for the dry eye disease treatment DIQUAS LX ophthalmic solution in Japan. This solution is the improved formulation that has reduced dosing frequency and improved patient compliance.

Ophthalmic Drugs Market Report Highlights:

• Anti-VEGF agents segment held the largest share in 2022 owing to their rising demand and lesser adverse effects
• Retinal disorders held the largest market share in 2022 owing to the rising prevalence of age-related macular degeneration and diabetic retinopathy
• The topical route of administration dominated the market in 2022 owing to factors such as the benefits of the topical route as it delivers the drug to the targeted site and ease of use
• The eye drops segment is expected to hold the largest share in 2022 owing to rising demand for eye drops, high patient compliance, and availability of OTC products
• Asia Pacific is expected to exhibit the fastest growth over the forecast period due to advancements in healthcare infrastructure, increasing demand for eye products, and a large patient pool

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Disease
  • 1.2.3. Route of Administration
  • 1.2.4. Dosage Type
  • 1.2.5. Product Type
  • 1.2.6. Product
  • 1.2.7. Regional scope
  • 1.2.8. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug class and disease outlook
  • 2.2.2. Route of administration and dosage type outlook
  • 2.2.3. Product type and product outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Ophthalmic Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing disease prevalence
    • 3.2.1.2. Strong developmental pipeline
    • 3.2.1.3. Advancement in drug delivery
    • 3.2.1.4. Promising investment scenario
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Patent expiry of blockbuster drugs
• 3.3. Ophthalmic Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis
  • 3.3.4. Pipeline Analysis
  • 3.3.5. Patent Expiry Analysis

Chapter 4. Ophthalmic Drugs Market: Drug Class Estimates & Trend Analysis

• 4.1. Drug Class Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Ophthalmic Drugs Market by Drug Class Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Anti-allergy
    • 4.4.1.1. Anti-allergy market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.2. Anti-VEGF Agents
    • 4.4.2.1. Anti-VEGF agents market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.3. Anti-inflammatory
    • 4.4.3.1. Anti-inflammatory market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3.2. Non-steroidal drugs
    • 4.4.3.2.1. Non-steroidal drugs market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3.3. Steroids
    • 4.4.3.3.1. Steroids market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.4. Anti- glaucoma
    • 4.4.4.1. Anti- glaucoma market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.5. Gene and Cell Therapy
    • 4.4.5.1. Gene and cell therapy market estimates and forecasts 2018 to 2030 (USD Billion)
  • 4.4.6. Others
    • 4.4.6.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Ophthalmic Drugs Market: Disease Estimates & Trend Analysis

• 5.1. Disease Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Ophthalmic Drugs Market by Disease Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Dry Eye
    • 5.4.1.1. Dry eye market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.2. Allergies
    • 5.4.2.1. Allergies market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.3. Glaucoma
    • 5.4.3.1. Glaucoma market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.4. Infection
    • 5.4.4.1. Infection market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.5. Retinal Disorders
    • 5.4.5.1. Retinal disorders market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.5.2. Macular Degeneration
    • 5.4.5.2.1. Macular degeneration market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.5.3. Diabetic Retinopathy
    • 5.4.5.3.1. Diabetic retinopathy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.5.4. Others
    • 5.4.5.4.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.6. Uveitis
    • 5.4.6.1. Uveitis market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.7. Others
    • 5.4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Ophthalmic Drugs Market: Route of Administration Estimates & Trend Analysis

• 6.1. Route of Administration Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Ophthalmic Drugs Market by Route of Administration Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Topical
    • 6.4.1.1. Topical market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.2. Local Ocular
    • 6.4.2.1. Local ocular market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.2.2. Subconjunctival
    • 6.4.2.2.1. Subconjunctival market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.2.3. Intravitreal
    • 6.4.2.3.1. Intravitreal market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.2.4. Retrobulbar
    • 6.4.2.4.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.2.5. Intracameral
    • 6.4.2.5.1. Intracameral market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.3. Systemic
    • 6.4.3.1. Systemic market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Ophthalmic Drugs Market: Dosage Type Estimates & Trend Analysis

• 7.1. Dosage Type Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Ophthalmic Drugs Market by Dosage Type Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Gels
    • 7.4.1.1. Gels market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.2. Eye Solutions and Suspensions
    • 7.4.2.1. Eye solutions and suspensions market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.3. Capsules and Tablets
    • 7.4.3.1. Capsules and tablets market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.4. Eye Drops
    • 7.4.4.1. Eye drops market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.5. Ointments
    • 7.4.5.1. Ointments market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Ophthalmic Drugs Market: Product Type Estimates & Trend Analysis

• 8.1. Product Type Market Share, 2023 & 2030
• 8.2. Segment Dashboard
• 8.3. Global Ophthalmic Drugs Market by Product Type Outlook
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.4.1. OTC
    • 8.4.1.1. OTC market estimates and forecasts 2018 to 2030 (USD Billion)
  • 8.4.2. Prescription Drugs
    • 8.4.2.1. Prescription drugs market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 9. Ophthalmic Drugs Market: Product Estimates & Trend Analysis

• 9.1. Product Market Share, 2023 & 2030
• 9.2. Segment Dashboard
• 9.3. Global Ophthalmic Drugs Market by Product Outlook
• 9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 9.4.1. Branded Drugs
    • 9.4.1.1. Branded drugs market estimates and forecasts 2018 to 2030 (USD Billion)
  • 9.4.2. Generic Drugs
    • 9.4.2.1. Generic drugs market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 10. Ophthalmic Drugs Market: Regional Estimates & Trend Analysis

• 10.1. Regional Market Share Analysis, 2023 & 2030
• 10.2. Regional Market Dashboard
• 10.3. Global Regional Market Snapshot
• 10.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 10.5. North America
  • 10.5.1. U.S.
    • 10.5.1.1. Key country dynamics
    • 10.5.1.2. Regulatory framework/ reimbursement structure
    • 10.5.1.3. Competitive scenario
    • 10.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.5.2. Canada
    • 10.5.2.1. Key country dynamics
    • 10.5.2.2. Regulatory framework/ reimbursement structure
    • 10.5.2.3. Competitive scenario
    • 10.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
• 10.6. Europe
  • 10.6.1. UK
    • 10.6.1.1. Key country dynamics
    • 10.6.1.2. Regulatory framework/ reimbursement structure
    • 10.6.1.3. Competitive scenario
    • 10.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.6.2. Germany
    • 10.6.2.1. Key country dynamics
    • 10.6.2.2. Regulatory framework/ reimbursement structure
    • 10.6.2.3. Competitive scenario
    • 10.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.6.3. France
    • 10.6.3.1. Key country dynamics
    • 10.6.3.2. Regulatory framework/ reimbursement structure
    • 10.6.3.3. Competitive scenario
    • 10.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.6.4. Italy
    • 10.6.4.1. Key country dynamics
    • 10.6.4.2. Regulatory framework/ reimbursement structure
    • 10.6.4.3. Competitive scenario
    • 10.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.6.5. Spain
    • 10.6.5.1. Key country dynamics
    • 10.6.5.2. Regulatory framework/ reimbursement structure
    • 10.6.5.3. Competitive scenario
    • 10.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.6.6. Norway
    • 10.6.6.1. Key country dynamics
    • 10.6.6.2. Regulatory framework/ reimbursement structure
    • 10.6.6.3. Competitive scenario
    • 10.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.6.7. Sweden
    • 10.6.7.1. Key country dynamics
    • 10.6.7.2. Regulatory framework/ reimbursement structure
    • 10.6.7.3. Competitive scenario
    • 10.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.6.8. Denmark
    • 10.6.8.1. Key country dynamics
    • 10.6.8.2. Regulatory framework/ reimbursement structure
    • 10.6.8.3. Competitive scenario
    • 10.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
• 10.7. Asia Pacific
  • 10.7.1. Japan
    • 10.7.1.1. Key country dynamics
    • 10.7.1.2. Regulatory framework/ reimbursement structure
    • 10.7.1.3. Competitive scenario
    • 10.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.7.2. China
    • 10.7.2.1. Key country dynamics
    • 10.7.2.2. Regulatory framework/ reimbursement structure
    • 10.7.2.3. Competitive scenario
    • 10.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.7.3. India
    • 10.7.3.1. Key country dynamics
    • 10.7.3.2. Regulatory framework/ reimbursement structure
    • 10.7.3.3. Competitive scenario
    • 10.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.7.4. Australia
    • 10.7.4.1. Key country dynamics
    • 10.7.4.2. Regulatory framework/ reimbursement structure
    • 10.7.4.3. Competitive scenario
    • 10.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.7.5. South Korea
    • 10.7.5.1. Key country dynamics
    • 10.7.5.2. Regulatory framework/ reimbursement structure
    • 10.7.5.3. Competitive scenario
    • 10.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.7.6. Thailand
    • 10.7.6.1. Key country dynamics
    • 10.7.6.2. Regulatory framework/ reimbursement structure
    • 10.7.6.3. Competitive scenario
    • 10.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
• 10.8. Latin America
  • 10.8.1. Brazil
    • 10.8.1.1. Key country dynamics
    • 10.8.1.2. Regulatory framework/ reimbursement structure
    • 10.8.1.3. Competitive scenario
    • 10.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.8.2. Mexico
    • 10.8.2.1. Key country dynamics
    • 10.8.2.2. Regulatory framework/ reimbursement structure
    • 10.8.2.3. Competitive scenario
    • 10.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.8.3. Argentina
    • 10.8.3.1. Key country dynamics
    • 10.8.3.2. Regulatory framework/ reimbursement structure
    • 10.8.3.3. Competitive scenario
    • 10.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
• 10.9. MEA
  • 10.9.1. South Africa
    • 10.9.1.1. Key country dynamics
    • 10.9.1.2. Regulatory framework/ reimbursement structure
    • 10.9.1.3. Competitive scenario
    • 10.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.9.2. Saudi Arabia
    • 10.9.2.1. Key country dynamics
    • 10.9.2.2. Regulatory framework/ reimbursement structure
    • 10.9.2.3. Competitive scenario
    • 10.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.9.3. UAE
    • 10.9.3.1. Key country dynamics
    • 10.9.3.2. Regulatory framework/ reimbursement structure
    • 10.9.3.3. Competitive scenario
    • 10.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.9.4. Kuwait
    • 10.9.4.1. Key country dynamics
    • 10.9.4.2. Regulatory framework/ reimbursement structure
    • 10.9.4.3. Competitive scenario
    • 10.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 11. Competitive Landscape

• 11.1. Recent Developments & Impact Analysis, By Key Market Participants
• 11.2. Company/Competition Categorization
• 11.3. Vendor Landscape
  • 11.3.1. List of key distributors and channel partners
  • 11.3.2. Key customers
  • 11.3.3. Key company market share analysis, 2023
  • 11.3.4. Pfizer Inc.
    • 11.3.4.1. Company overview
    • 11.3.4.2. Financial performance
    • 11.3.4.3. Product benchmarking
    • 11.3.4.4. Strategic initiatives
  • 11.3.5. Alcon
    • 11.3.5.1. Company overview
    • 11.3.5.2. Financial performance
    • 11.3.5.3. Product benchmarking
    • 11.3.5.4. Strategic initiatives
  • 11.3.6. Novartis AG
    • 11.3.6.1. Company overview
    • 11.3.6.2. Financial performance
    • 11.3.6.3. Product benchmarking
    • 11.3.6.4. Strategic initiatives
  • 11.3.7. Bausch Health Companies Inc.
    • 11.3.7.1. Company overview
    • 11.3.7.2. Financial performance
    • 11.3.7.3. Product benchmarking
    • 11.3.7.4. Strategic initiatives
  • 11.3.8. Merck & Co., Inc.
    • 11.3.8.1. Company overview
    • 11.3.8.2. Financial performance
    • 11.3.8.3. Product benchmarking
    • 11.3.8.4. Strategic initiatives
  • 11.3.9. Regeneron Pharmaceuticals Inc.
    • 11.3.9.1. Company overview
    • 11.3.9.2. Financial performance
    • 11.3.9.3. Product benchmarking
    • 11.3.9.4. Strategic initiatives
  • 11.3.10. Allergan (AbbVie Inc)
    • 11.3.10.1. Company overview
    • 11.3.10.2. Financial performance
    • 11.3.10.3. Product benchmarking
    • 11.3.10.4. Strategic initiatives
  • 11.3.11. Bayer AG
    • 11.3.11.1. Company overview
    • 11.3.11.2. Financial performance
    • 11.3.11.3. Product benchmarking
    • 11.3.11.4. Strategic initiatives
  • 11.3.12. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
    • 11.3.12.1. Company overview
    • 11.3.12.2. Financial performance
    • 11.3.12.3. Product benchmarking
    • 11.3.12.4. Strategic initiatives
  • 11.3.13. Nicox
    • 11.3.13.1. Company overview
    • 11.3.13.2. Financial performance
    • 11.3.13.3. Product benchmarking
    • 11.3.13.4. Strategic initiatives
  • 11.3.14. Coherus BioSciences
    • 11.3.14.1. Company overview
    • 11.3.14.2. Financial performance
    • 11.3.14.3. Product benchmarking
    • 11.3.14.4. Strategic initiatives